SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending amid anticipation for upcoming HOPE-3 trial data, with the community actively debating potential outcomes and the impact of a recent short report. Discussions revolve around the trial's key endpoints, potential FDA decisions, and the possibility of a short squeeze. Some traders speculate about leaked data or pre-announcements, contributing to the stock's volatility.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is trending due to concerns about satellite launch delays and the company's communication strategy, causing some investors to question management's credibility. The community is debating the feasibility of ASTS's production ramp-up and potential competition from Starlink. Despite these concerns, some bulls remain optimistic about the long-term potential and upcoming launches.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB's stock is trending following strong earnings results and raised guidance, fueled by growth in its Atlas cloud database service. Community discussion revolves around the magnitude of the after-hours jump and potential for continued upside, with some expressing concerns about valuation. The stock is also getting attention for its potential in storing AI databases and its integration with cloud services, impacting broader software and database sectors.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE Crypto is trending as its community rallies around rebuilding internet culture and meme traditions within Web3. The community emphasizes its dedication and consistency, highlighting its presence even when markets are down. Discussions also focus on the potential for significant growth and a return to OG memes, with community members expressing strong conviction.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is trending as investors discuss its lawsuit against the Trump administration over tariff refunds and debate its high P/E ratio relative to other retailers. Community members are also weighing in on strong sales numbers, potential special dividends, and the impact of consumer spending trends on the stock's performance. Some are closely watching for a potential breakout, while others express concern about the stock's recent struggles to maintain gains.

Based Chad

Based Chad is trending as community members highlight its strong performance, particularly relative to Ethereum and other meme coins, with some noting the involvement of Coinbase executives. Conversations mention a potential supply shock and the upcoming release of a video game, fueling bullish sentiment. The meme's widespread recognition and cultural relevance are also frequently cited as reasons for its potential.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

CRDO is trending after a strong earnings report, with revenue and EPS exceeding expectations, driven by AI infrastructure demand. The community is discussing the company's growth potential and comparing it to competitors, while also acknowledging potential overvaluation. Positive sentiment is fueled by increased adoption of active electrical cables (AECs) by hyperscalers and strategic partnerships within the AI sector.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis ($ALMS) is trending due to positive insider buying activity and upcoming Phase 3 data readout, sparking comparisons to TERN. Community members are closely watching insider transactions and potential partner news, while some anticipate a short squeeze. Bullish sentiment is fueled by upcoming catalysts and a possible rotation into biotech.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is trending due to community excitement around its potential as foundational infrastructure for TradFi, emphasized by its high throughput and compliance-aware design. Investors are actively discussing the token's value proposition in comparison to major platforms like Amazon, Google, and Microsoft, viewing KTA as a targeted bet on the future of financial plumbing. The community also highlights potential partnerships, particularly with Stripe, as a key catalyst.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as it nears all-time highs, driven by renewed optimism around its AI strategy following leadership changes and anticipation for a product supercycle in 2025. The community is actively discussing potential breakout levels and analyst price targets, while some express concerns about valuation and competition. Investors are weighing the company's strong financials and AI potential against potential headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Applied Therapeutics (APLT) Upgraded to Buy: Here's Why

Applied Therapeutics (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

<ul class="summary-bullets"><li>The company stated that there is no deadline for the strategic alternative finding process.</li><li>The firm also noted that it intends to request an additional meeting with the FDA to decide on a design for its late-stage study of Govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency.</li></ul> Applied Therapeutics, Inc. (APLT) said on Thursday that it is laying off approximately 46% of its workforce as it seeks to conserve cash, while its Board of Directors explores strategic alternatives for the company.The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions to maximise shareholder value, the company<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/20/3191771/0/en/Applied-Therapeutics-Announces-Corporate-Updates.html"> said</a>. There is no deadline for the process, Applied Therapeutics noted, while also adding that the review might not result in a transaction.<h2 class="st-heading-2">Drug Pipeline Updates</h2>The company also said it intends to request an additional meeting with the U.S. Food and Drug Administration to decide on a design for its late-stage study of Govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase (SORD) Deficiency. In this disorder, the body can’t properly metabolize sorbitol, leading to its toxic accumulation that damages peripheral nerves and causes progressive symptoms like limb weakness, numbness, and difficulty walking.The company held a meeting with the FDA in the third quarter and is now evaluating the meeting minutes and follow-up correspondence.It is also evaluating the next steps for developing Govorestat for the treatment of Classic Galactosemia, a disorder in which the body cannot break down the sugar galactose. &nbsp;Govorestat is the company’s lead drug candidate for the treatment of CNS rare metabolic diseases or inherited conditions affecting the brain, such as Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency, and phosphomannomutase 2 congenital disorder of glycosylation.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/APLT">APLT shares</a> traded marginally in the red at the time of writing. On Stocktwits, retail sentiment stayed within the ‘extremely bullish’ territory over the past 12 months while message volume stayed at ‘extremely high’ levels.APLT shares fell 67% this year and by 97% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-procures-1.5-billion-loan-to-grow-its-pipeline-beyond-vaccines/cLPA0dfREaR">Moderna Secures $1.5B Credit Facility As It Seeks To Pivot Away From Vaccines</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Applied Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Applied Therapeutics To Lay Off Nearly Half Its Staff, Board Explores M&A Options

The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said.

Equity

The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said.


Applied Therapeutics Tanks As FDA Path For Lead Rare-Disease Drug Turns Uncertain

Applied Therapeutics stock falls after FDA feedback prompts another Type C meeting to discuss the Phase 3 plan for its CMT-SORD drug govorestat.read more...

Halper Sadeh LLC Encourages Applied Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Applied Therapeutics, Inc. (NASDAQ: APLT) breached their fiduciary duties to shareholders. If...

Retail buzz&nbsp;surrounding Applied Therapeutics Inc spiked&nbsp;late Sunday after the company revealed full 12-month clinical results alongside new 18- and 24-month topline data from&nbsp;a midstage trial of govorestat to treat Charcot-Marie-Tooth disease caused by Sorbitol Dehydrogenase deficiency (CMT-SORD).MRI observations showed that govorestat treatment slowed disease progression at 24 months, while keeping blood sorbitol levels low and improving functional outcomes and patient-reported metrics.The 12-month data revealed a statistically significant increase in the CMT-Health Index (CMT-HI) and a connection between sorbitol reductions and enhanced mobility and balance.&nbsp;CMT-SORD is a rare, progressive neuromuscular disorder that leads to nerve damage, muscle weakness, and mobility impairment.The company acknowledged that the primary endpoint of the 10MWRT at 12 months failed to show statistical significance, which led to its removal from the CMT-FOM clinical outcomes tool.Patients demonstrated good tolerance for govorestat, maintaining safety for two years.&nbsp;90% of eligible patients continued participating in the open-label extension study.&nbsp;Applied Therapeutics said it will submit a New Drug Application (NDA) for govorestat by 2025.The company’s shares surged 22.8% to close at $0.60 on Friday, with a further 1.2% gain in after-hours trading.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘a 629% surge in 24-hour message volume.Some retail traders expressed optimism about Applied Therapeutics' prospects, with one suggesting that the stock’s sharp decline in December may have been overdone and that the current low valuation presents a “monster opportunity.”<stembedurl>https://stocktwits.com/BuyThemCheapStackemDeep/message/615044473</stembedurl>Another pointed to the positive impact of govorestat on disease progression in CMT-SORD, noting that in a rare condition with no approved treatments, the available data could support regulatory approval.<stembedurl>https://stocktwits.com/Aawilliam2003/message/615043651</stembedurl>The stock has declined 33% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug

The company said that Govorestat slowed disease progression and improved patient outcomes in CMT-SORD, a rare hereditary neuropathy. The company plans to submit an NDA in 2025 amid strong retail investor interest.

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Applied Therapeutics, Inc. (Applied Therapeutics or the Company) (NASDAQ: APLT) and reminds...

Class Action Filed Against Applied Therapeutics, Inc. (APLT) - February 18, 2025 Deadline to Join - Contact Levi & Korsinsky

Class Action Filed Against Applied Therapeutics, Inc. (APLT) - February 18, 2025 Deadline to Join - Contact Levi & Korsinsky Class Action Filed Against Applied Therapeutics, Inc. (APLT) - February...

INVESTOR DEADLINE TOMORROW: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - APLT

INVESTOR DEADLINE TOMORROW: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - APLT INVESTOR DEADLINE TOMORROW: Applied Therapeutics, Inc...

APLT Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Filing Deadline in Class Action Lawsuit

APLT Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Filing Deadline in Class Action Lawsuit APLT Deadline in 2 Days: Kessler Topaz...

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Applied Therapeutics Inc

$CRWD

$CRM

$SNOW

$MDB

Which earnings report are you most looking forward to this week? 
 
Drop a comment for others.

Current Price	$0.2412
Prev Close	$0.26
Open	$0.2504
Dividend Yield	0.00%
50-Day Moving Average	$0.836
Beta	1.16
Avg. Volume	26.72M
PE Ratio	-2.41

52-Week High	$1.75
52-Week Low	$0.2182
Market Capitalization	$37.52M
EPS (Annual)	-$0.757
Price to Book	-62.01
Revenue Per Employee	$13,000.00
Enterprise Value/EBITDA	N/A

APLT
Applied Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest APLT News

APLTApplied Therapeutics Inc